SCHEMBL30765802

SCHEMBL30765802

CCCCOC(=O)Cn1c(Br)cnc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 3/20 0.38
MAPT P10636 4/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765729 0.86 ALDH1A1 (0.38) KMT2ALMNAMAPTNPSR1GABRP
SCHEMBL30766079 0.86 TSHR (0.38) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765882 0.85 SOS1 (0.37) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765922 0.84 LMNA (0.39) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765758 0.84 L3MBTL1 (0.40) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765510 0.83 L3MBTL1 (0.41) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765468 0.83 LMNA (0.40) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30766030 0.82 L3MBTL1 (0.40) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765675 0.82 L3MBTL1 (0.40) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765767 0.82 GAA (0.40) GAAL3MBTL1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed